IXICO, a London-based digital technology company that focuses on neuroscience, has garnered a contract to perform imaging clinical trial services for Araclon, a biotech company based in Zaragoza, Spain, according to an article by Angus Liu, associate editor of Fierce Biotech .
Per IXICO’s website, the public company’s “medical image management and analysis products are used by the global pharmaceutical industry to select patients for clinical trials and to assess the safety and efficacy of drugs in development.” Its proprietary technologies – TrialWire™ and TrialTracker™ – have been used to collect patient data from more than 400 hospital sites worldwide in large clinical trials of Alzheimer’s disease treatments.
After receiving approval from the Spanish Agency of Medicinal Products and Medical Devices, Araclon will conduct the phase 2 clinical trial on its Alzheimer’s vaccine candidate dubbed ABvac40. A total of 120 patients with mild cognitive impairment (MCI) from 22 European facilities will participate in the clinical trial, which is designed to establish the dosage regimen for the therapy and to confirm the treatment safety and tolerability data obtained in phase I. Results from phase I, presented in July 2016, confirmed that ABvac40 produced an immune response in more than 87 percent of participants who received the active ingredient.
For the clinical trial, IXICO will use its imaging data management platform TrialTracker to collate results from positron emission tomography (PET) and MRI scans and its image analysis technology to evaluate patient eligibility, assess target engagement and quantify drug effects in patients. The company has offered end-to-end imaging services to the biopharma industry, academia and medical charities since 2004. Ixico embarked on London Stock Exchange’s AIM for smaller growing companies in 2013 through a reverse takeover of Phytopharm.
IXICO is engaged in clinical data management and analysis for neurodegenerative diseases, including Huntington’s, multiple sclerosis and Alzheimer’s, as well as the diagnosis and management of dementia in clinical practice. The company also offers an EU CE-marked medical device called Assessa that assists helps healthcare professionals in measuring information about the brain, diagnosing neurological disorders and detecting the underlying causes.
IXICO reportedly maintains commercial relationships with nine of the top 15 pharmaceutical companies. In August 2015, the company signed a $1 million-per-year partner agreement that runs at least seven years with a leading global pharmaceutical company. IXICO reported £3.1 million (approximately $4 million) in revenue and the establishment of four new contracts in Alzheimer’s clinical trials with a combined value of over £3 million in 2016. In March 2017, he company signed a new deal worth $1.5 million with an existing top 10 pharma client.
Unlike most Alzheimer’s therapies currently being developed, the Araclon candidate targets the amyloid-beta 40 protein using the C-terminal part of the amyloid-beta peptide as vaccine antigen instead of the N-terminal fragment. According to Araclon’s CSO Manuel Sarasa, the project is also supported by some Spanish institutions such as the Zaragoza University. Araclon is also developing an immunotherapy agent against the amyloid-beta-42 protein.